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A B S T R A C T
Purpose
This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity
of daily oral dosing with lapatinib (GW572016) in patients with ErbB1-expressing and/or
ErbB2-overexpressing advanced-stage refractory solid tumors.
Patients and Methods
Heavily pretreated patients with ErbB1-expressing and/or ErbB2-overexpressing metastatic
cancers were randomly assigned to one of five dose cohorts of lapatinib administered once daily.
Pharmacokinetic samples were obtained on days 1 and 20. Clinical response was assessed
every 8 weeks.
Results
Sixty-seven patients with metastatic solid tumors were treated with lapatinib. The most fre-
quently reported drug-related adverse events were diarrhea (42%) and rash (31%). No grade
4 drug-related adverse events were reported. Five grade 3 drug-related toxicities (gastrointes-
tinaleventsandrash)wereexperiencedby fourpatients.Drug-relatedinterstitialpneumonitisor
cardiac dysfunction associated with other ErbB-targeted therapies was not reported. Four pa-
tients with trastuzumab-resistant metastatic breast cancer—two of whom were classified
as having inflammatory breast cancer—had partial responses (PRs). Twenty-four patients with
various other carcinomas experienced stable disease, of whom 10 received lapatinib for $ 6
months.The relationshipsbetween lapatinibdose or serumconcentrationand clinical response
could not be adequately characterized due to the limited response data. The incidence of diar-
rhea increased with increasing dose, whereas the incidence of rash was not related to dose.
Conclusion
Lapatinib was well tolerated at doses ranging from 500 to 1,600 mg once daily. Clinical activity
was observed in heavily pretreated patients with ErbB1-expressing and/or ErbB2-overex-
pressing metastatic cancers, including four PRs in patients with trastuzumab-resistant breast
cancers and prolonged stable disease in 10 patients.
J Clin Oncol 23:5305-5313.  2005 by American Society of Clinical Oncology
INTRODUCTION
In humans, the ErbB family of transmem-
brane tyrosine kinase receptors consists of
four members: ErbB1 (epidermal growth
factor receptor [EGFR]), ErbB2, ErbB3,
and ErbB4.1,2 Expression of ErbB1 and/or
overexpression of ErbB2 occur to varying
degrees in epithelial malignancies, where
they promote tumor cell growth/survival,
and in certain tumors predict for a poor
clinical outcome.3-6 Upon ligand binding,
ErbBreceptors formhetero-or homodimers
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resulting in the autophosphorylation of specific tyrosine
residues within the conserved catalytic kinase domains
of ErbB receptors.1,7 These phosphorylated tyrosine resi-
dues serve as docking sites for Src-homology 2 and
phosphotyrosine-binding domain–containing proteins
that link activated ErbB receptors to downstream cell pro-
liferation (mitogen-activated protein kinase [MAPK]) and
survival (phosphotidylinositol-3-kinase [PI3K]) path-
ways.1,2,7-12 The established role of ErbB1 and ErbB2 in
promoting the growth and survival of various types of
solid tumors makes them attractive therapeutic targets.
Monoclonal antibodies such as cetuximab and trastuzumab
targeting ErbB1 and ErbB2, respectively, as well as small-
molecule tyrosine kinase inhibitors of ErbB1 (eg, gefitinib
and erlotinib) have been shown to inhibit proliferation of
ErbB1- or ErbB2-expressing cancer cells.13-17 Moreover,
clinical studies have demonstrated the activity of
these ErbB-targeted agents in patients with advanced
stage malignancies.18-22
Lapatinib (GW572016) is anorallyactive smallmolecule
that reversibly inhibits ErbB1 and ErbB2 tyrosine kinases,
leading to inhibition of MAPK and PI3K signaling in
ErbB1-expressing andErbB2-overexpressing tumor cell lines
and xenografts.23,24 Lapatinib-treated tumor cells undergo
apoptosis or growth arrest depending upon the cell
type.23,24 ErbB2, the onlymember of theErbB familywithout
anexogenous ligand, is the preferredheterodimerpartner for
other ErbB receptors where it amplifies the biologic signal.1,7
Since ErbB2-containing heterodimers exert potent growth
and survival effects, simultaneous inhibition of ErbB2 and
ErbB1 is an appealing therapeutic strategy.
In phase I studies in healthy volunteers, lapatinib was
well tolerated at repeat doses up to the highest dose ad-
ministered (175 mg/d).25 In the first phase I dose escala-
tion study in cancer patients (EGF10003), lapatinib was
well tolerated at doses up to the highest dose administered
(1,800 mg once daily) with mild and transient diarrhea,
nausea, rash, fatigue, anorexia, and vomiting as the pre-
dominant toxicities.26 Clinical activity was observed at
doses of 650 mg/day and higher.26
Pharmacokinetic data from these studies indicated that
serum lapatinib concentrations peak 4 hours after dosing,
increase with increasing dose, accumulate approximately
two-fold with daily dosing, and achieve steady state in 6
to 7 days, suggesting an effective half-life of 24 hours.
This study (EGF10004) was designed to (1) assess the
safety and tolerability of lapatinib after multiple dosing;
(2) assess the pharmacokinetics of lapatinib; (3) evaluate
the biologic effects of lapatinib in serial tumor biopsies;
(4) determine a biologically active dose range for lapatinib;
and (5) assess the clinical activity of lapatinib. The biologic
effects of lapatinib on signaling pathways in tumor tissue
obtained from a subset of 33 patients participating in
this study who had sequential biopsies were recently re-
ported.27 The safety/tolerability, pharmacokinetics, and
clinical activity of lapatinib are reported here.
PATIENTS AND METHODS
Eligibility Criteria
Patients enrolled in this study were males or females age 18
years or older with a histologically-confirmed diagnosis of cancer;
had an archived or fresh biopsy that demonstrated expression of
ErbB1 (positive by immunohistochemistry [IHC]) and/or overex-
pression of ErbB2 (2 or 3 by IHC) or that displayed gene am-
plification of ErbB2 by fluorescence in situ hybridization; had
a Karnofsky performance status $ 70%; had a life expectancy
of at least 12 weeks; had a hemoglobin concentration $ 9 g/dL
(5 mmol/L), an absolute granulocyte count $ 1,500/mm3
(1.5  109/L), a platelet count $ 100,000/mm3 (100  109/L);
and were able to swallow and retain oral medication. Patients
were excluded from the study if they were pregnant or lactating
females; had malabsorption syndrome; received any chemother-
apy within the previous 4 weeks or treatment with nitrosourea or
mitomycin within the previous 6 weeks; received biologic, hor-
monal, or radiation therapy within the previous 4weeks; were tak-
ing steroids; had a total bilirubin 2 mg/dL; had AST or ALT
3 the upper limit of normal; had a class III or IV heart failure as
defined by the New York Heart Association functional classifica-
tion system; or had a left ventricular ejection fraction (LVEF) 
40%. All patients provided a signed informed consent.
The study protocol was approved by institutional review
boards at the following institutions: TriStar Nashville Market,
Nashville, TN; Duke University Health System, Durham; Univer-
sity of North Carolina School of Medicine, Chapel Hill, NC; and
University Hospitals of Cleveland, Cleveland, OH. The study was
conducted in accordance with the 1996 version of the Declara-
tion of Helsinki.
Safety Assessments
Patients underwent a physical examination, vital sign mea-
surements, Karnofsky performance status, basic ophthalmologic
examination, 12-lead ECG, multigated angiogram (MUGA) scan,
hematology, clinical chemistry, and urinalysis performed within
14 days before the first dose of study drug. Physical examination,
vital signs, and safety laboratory evaluations were repeated on days
1 and 20. Adverse events (AEs) were graded using the National
Cancer Institute Common Toxicity Criteria version 2.0. Patients
who continued therapy after Day 21 had safety assessments per-
formed every 4 weeks. ECG and MUGA scans were repeated
every 8 weeks during treatment. A poststudy evaluation was re-
quired 28 days after the last dose of lapatinib was administered.
Study Treatments
This was a randomized, parallel-group, repeated dose-
ranging study in patients with solid tumors. Lapatinib
(GlaxoSmithKline, Research Triangle Park, NC) was supplied
as 100-mg and 250-mg tablets for daily oral administration.
Sixty-seven patients were randomly assigned to receive one of
five oral doses of lapatinib administered daily for 21 days. The
doses administered were chosen on the basis of safety, tolerabil-
ity, and pharmacokinetic data from prior healthy volunteer25 and
cancer patient26 studies, and included 500, 650, 900, 1,200, and
1,600 mg of lapatinib. The protocol allowed investigator discre-
tion in making upward dose adjustments in patients who were
Burris et al
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assessed as having progressive disease. An amendment was writ-
ten, but not fully implemented, that included two additional dose
groups of 1,000 and 2,000 mg of lapatinib administered daily. Af-
ter completing the initial 21-day portion of the study, patients
continued on once-daily lapatinib therapy until disease progres-
sion, treatment-emergent toxicities, or withdrawal of consent.
Pharmacokinetic Assessments
Blood samples were taken for determination of serum lapati-
nib concentration on days 1 and 20 before dosing, and at 0.5, 0.75,
1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing. Serum
was separated and stored at20°C until analysis. Concentrations
of lapatinib were measured by liquid chromatography tandem
mass spectrometry with parallel online turbulent flow extraction
and positive ion selected reaction monitoring, as previously de-
scribed.28 The calibration range of the lapatinib assay was 1 to
1,000 ng/mL. Interassay precision was within 12%, and interassay
accuracy was within 8% of nominal. Pharmacokinetic analyses
were performed usingWinNonlin 3.2 software (Pharsight, Moun-
tain View, CA). Standard noncompartmental methods were used
to calculate area under the serum concentration versus time curve
within the dosing interval (AUC), peak serum concentration
(Cmax), the time at which Cmax occurred (tmax) on days 1 and
20, and steady-state trough concentration (Cmin) on day 20.
Evaluation of Clinical Activity
Disease status was assessed predose, after 8 weeks of therapy,
and every 8 weeks thereafter until withdrawal from the study us-
ing the Response Evaluation Criteria in Solid Tumors (RECIST)
Guidelines.29 Patients who did not have lesions that were assess-
able by RECIST (eg, dermatologic changes consistent with in-
flammatory breast cancer) were evaluated by clinical assessment.
RESULTS
Patient Characteristics
Sixty-seven patients were enrolled at four sites in the
United States betweenMarch 2002 and May 2003. Patients
were randomly assigned to one of five daily dose cohorts
(500 mg [n Z 13], 650 mg [n Z 15], 900 mg [n Z 11],
1,200 mg [nZ 12], and 1,600 mg [nZ 13]), with the later
addition of a cohort at 1,000 mg daily (n Z 3). Patient
characteristics are shown in Table 1. The study population
included patients with a variety of solid tumors, with
breast cancer being the most common (n Z 30). The pa-
tient population was heavily pretreated, with 66 patients
(99%) having received previous chemotherapy. These
patients received a median of five prior therapies with a
range of one to 14.
Safety and Tolerability
Forty-four (66%) of 67 patients experienced drug-
related AEs. The most frequently reported drug-related
AEs were diarrhea (42%) and rash (31%) (Table 2). Other
drug-related AEs included nausea (13%) and fatigue
(10%); all remaining drug-related AEs occurred with an
incidence of 5% or less. Most drug-related AEs (135 of
140) were mild in intensity (grade 1 or 2). Five grade 3
AEs experienced by four patients were considered to be
drug-related: one patient had grade 3 abdominal pain at
the 650-mg dose level, one patient had grade 3 rash and
grade 3 diarrhea at the 1,000-mg dose level that required
a dose reduction to 500 mg; one patient had grade 3 di-
arrhea at the 1,200-mg dose level that required temporary
interruption of lapatinib (the patient continued to experi-
ence grade 2 diarrhea at a reduced dose of 650 mg and was
subsequently withdrawn); one patient who initially re-
ceived 900 mg and subsequently received 1,600 mg lapa-
tinib was withdrawn due to grade 3 gastroesophageal
reflux disease. The gastrointestinal reflux was believed
by the investigator to be related to the large pill burden.
















Male 3 4 4 0 3 4
Female 10 11 7 3 9 9
Age, years
Median 56 60 57 53 54 55
Range 28-74 37-82 34-82 43-59 37-67 38-70
Prior treatments
Median 6 7 5 6 4 5
Range 2-10 1-11 1-13 0-9 1-14 2-10
Disease site
Breast 6 6 5 3 6 4
AUP 1 1 2 0 0 1
CRC 2 2 1 0 1 1
H&N 0 1 0 0 2 2
Ovarian 1 1 1 0 0 1
Lung 1 2 2 0 2 3
Other 2 0 0 0 1 1
Abbreviations: AUP, adenocarcinoma of unknown primary origin; CRC,
colorectal cancer; H&N, head and neck carcinoma.
Table 2. No. of Patients with Drug-Related Adverse Events That Occurred in $ 5% of Patients Receiving Lapatinib
Dose (mg)* N Z 67
Adverse Event 500 (n Z 13) 650 (n Z 15) 900 (n Z 11) 1,000 (n Z 3) 1,200 (n Z 12) 1,600 (n Z 13) Total Grade 3 events†
Diarrhea 4 5 3 2 5 9 28 2
Rash 5 5 3 3 2 3 21 1
Nausea 1 3 2 1 1 1 9 0
Fatigue 0 2 2 1 1 1 7 0
*Adverse events were summarized by the dose to which the patient was initially assigned. Dose adjustments were permitted; therefore, patients in the
lower dose groups may also have received higher doses of lapatinib during the course of their treatment.
†Grade 3 adverse events were evaluated using the National Cancer Institute Common Toxicity Criteria version 2.0 (NCI CTC).
Study of Lapatinib in Metastatic Carcinomas
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No grade 4 drug-related AEs were reported. No additional
temporary treatment interruptions, dose-reductions, or
withdrawals were associated with drug-related AEs.
Drug-related rash (rash, acne, dermatitis acneiform)
was reported in 21 (31%) of 67 patients and was generally
mild or moderate (grade 1 or 2) in intensity; only one
grade 3 rash was reported (as described in the preceding
paragraph). In most patients, the onset of rash occurred
between days 2 and 66 and generally resolved without
interrupting treatment. Five patients with one or more
drug-related skin rash AEs received treatment with derma-
tologic medications without resolution. The rash remained
unresolved at the timeof study termination in threepatients
who did not receive dermatologic medications.
No significant drug-related reductions in LVEF or
drug-related occurrences of interstitial pneumonitis were
reported; one patient experienced an asymptomatic de-
crease in LVEF from 37% at baseline to 20% on day
140, which was reported to be related to underlying disease
and cor pulmonale rather than lapatinib. The patient,
who was granted a protocol exception at screening for
LVEF # 40%, continued treatment without interruption
until disease progression. The LVEF value returned to
near baseline by the time of study termination. Few
changes in clinical laboratory values were reported as
AEs during the study, and most of these laboratory
changes were not related to lapatinib. Three patients had
grade 1 anemia at the 500-, 900-, and 1,600-mg dose levels
that was considered to be drug-related. Grade 1 anemia re-
solved on the same day as onset in one patient (900 mg),
5 days after onset in the second patient (500 mg), and
remained unresolved in the third patient (1,600 mg). No
clinically significant changes in vital sign measurements
or ECG results were observed at any dose level, and no
patient had ophthalmologic abnormalities.
Only one of 53 serious AEs (grade 2 diarrhea at the
650-mg dose level) was considered to be related to lapati-
nib. The remainder of the serious AEs were due to hospi-
talizations for events related to disease progression. There
were seven deaths during the study, but none was consid-
ered drug-related.
Clinical Activity
Fifty-nine of 67 patients were assessable for disease
assessment. Four patients experienced partial responses.
All four had breast cancer, overexpressed ErbB2 (3 by
IHC), and with one exception, co-expressed ErbB1. Two
of the partial responders had recurrent inflammatory breast
cancer, based on clinical history and evidence of dermal-
lymphatic invasion on histopathology (Fig 1A). The
patients who achieved partial responses (PRs) also had
high expression of activated, phosphorylated ErbB2 that
was inhibited with lapatinib therapy (Fig 1B and 1C).
Detailed analysis of the biologic effects of lapatinib in this
study (EGF10004) was described recently.27 Figure 2 dem-
onstrates the clinical regressionobserved inonepatientwith
recurrent advanced stage inflammatory breast cancer. All
four partial responders were previously treated with trastu-
zumab, either alone or in combinationwithmultiple chem-
otherapeutic regimens (eg, anthracycline and/or taxane
based). The median duration of treatment for patients
with PR was 5.5 months (range, 3 to 8 months). Stable dis-
ease (SD) was reported in 24 patients (10 breast cancer, five




Fig 1. Representative histopathology and inhibition of activated, phosphor-
ylated ErbB2 (p-ErbB2) in a responding patient with breast cancer. (A)
Histopathology demonstrates dermal-lymphatic invasion consistent with
recurrent inflammatory breast cancer. Immunohistochemistry staining of
p-ErbB2 was performed from tumor biopsies on days 0 (B) and 21 (C) of
lapatinib therapy.27
Burris et al
5308 JOURNAL OF CLINICAL ONCOLOGY
Downloaded from jco.ascopubs.org on November 2, 2010. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
three head and neck cancer, one ovarian cancer, one adeno-
carcinoma of unknownprimary, and one granular cell carci-
noma). Twenty-two of 28patients who achieved either PRor
SD received lapatinib treatment for $ 3 months, and 12 of
these patients received treatment for$ 6 months, including
six patients with breast cancer, two with NSCLC, three with
head and neck cancer, and one with colorectal cancer (Table
3). Four patients received lapatinib treatment for more than
1 year, including a 62-year-old man with colorectal cancer
who received lapatinib for 15 months; a 55-year-old woman
withNSCLCwhoreceived lapatinib for12months; a44-year-
oldmanwithheadandneckcancerwhoreceived lapatinib for
21 months; and a 69-year-old woman with NSCLC who re-
ceived lapatinib for 18 months.
Before discontinuing therapy, the protocol allowed
investigator discretion for intrapatient dose escalation in
patients who were assessed as having progressive disease.
However, there was no instance in which this resulted
in an objective clinical response. At the investigators’ dis-
cretion, doses were increased after 1 to 3 months of treat-
ment in four patients with SD who continued with SD for
an additional 6 to 10 months.
Pharmacokinetics
Median steady-state (day 20) serum concentra-
tion profiles at each dose are shown in Figure 3. Serum con-
centrations peaked on average 3 to 6 hours postdose, and
repeated dosing resulted in an approximately two-fold ac-
cumulation on day 20 relative to day 1 (data not shown).
Steady-state AUC, Cmax, andCmin at each dose are summa-
rized in Table 4. Serum concentrations generally increased
with increasingdose, althoughvariabilitywashigh.Concen-
trations at the 1,200-mg dose were a notable exception, re-
sembling those at the 500 mg and 650 mg doses rather than




Fig 2. Clinical regression of breast cancer in a patient achieving a partial
response comparing day 0 (A) with 2 (B) and 4 (C) months on lapatinib therapy.
Table 3. Patients with Partial Responses or Stable Disease Receiving







650 Breast PR 8
1,200 Breast PR 6
900 Breast PR 6
1,200 Head and Neck SD 21
1,600 NSCLC SD 18
900 Colorectal SD 15
900 NSCLC SD 12
500 Breast SD 9.5
500 Head and Neck SD 9.5
500 Breast SD 7
1,200 Breast SD 6
1,200 Head and Neck SD 6
*Response was summarized by the dose to which the patient was
initially assigned. Dose adjustments were permitted; therefore, patients
in the lower dose groups may also have received higher doses of
lapatinib during the course of their treatment.
Abbreviations: PR, partial response; SD, stable disease; NSCLC, non–
small-cell lung cancer.
Study of Lapatinib in Metastatic Carcinomas
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Dose and Concentration Relationships With
Response and Toxicity
The frequency of clinical response, categorized as PR,
SD  6 months, or nonresponders, was examined in re-
lation to drug exposure, in terms of dose, and steady-state
AUC, Cmax, and Cmin. The relationship with dose (Fig 4)
indicates that the majority of responders (PR and SD  6
months) were receiving 1,200 mg daily (median dose in all
responders). The relationship with Cmin (Fig 5), which
demonstrated a right-skewed distribution, indicates that
the majority of responders displayed a trough concentra-
tion in the 0.3 to 0.6 g/mL range. The median dose in all
patients, as well as responders only, which produced a
Cmin in this range was 900 mg daily. Similar relationships
were observed with AUC and Cmax (data not shown).
Regression analysis suggested that the frequency of di-
arrhea was linearly related to dose (P  .03) over the 500
to 1,600 mg range. There was no apparent relationship of
diarrhea to serum concentration. The incidence of rash
showed no apparent relationship to dose or serum concen-
tration, or to clinical response as described for other EGFR
inhibitors. Figure 6 shows the incidence of clinical re-
sponse in relation to lapatinib dose categorized by oc-
currence of rash. The number of responders (PR and
SD 6 months either alone or combined) was larger with-
out rash compared to those with rash, demonstrating that
rash is not an indicator of clinical response to lapatinib.
DISCUSSION
Lapatinib was well tolerated in this study at doses up to
1600 mg daily with clinical activity observed at doses
ranging from 650 to 1,600 mg daily in heavily pretreated
patients with ErbB1-expressing and/or ErbB2-over-
expressing metastatic solid tumors. At doses where clinical
activity was observed, drug-related toxicity was primarily
restricted to grade 1 and 2 diarrhea (42%) and skin rash
(31%). No grade 4 toxicity was reported.
Four patients with advanced-stage breast cancer whose
disease had progressed on prior trastuzumab and taxane- or
anthracycline–based chemotherapy regimens, achieved a PR
with lapatinib. All of these patients had tumors that over-
expressed ErbB2, and with the one exception, co-expressed
ErbB1.27 In addition, these four patients exhibited baseline
expression of activated, phosphorylated ErbB2 that was in-
creasedcomparedwithnonresponders(Fig1).27Anadditional
24 patients experienced disease stabilization. Twelve of 28
patients with either a PR or SD received lapatinib for $ 6
months and four patients (NSCLC [nZ 2], colorectal, head





















6 12 18 24
Time (hours)
1,600 mg (n = 13)
1,200 mg (n = 8)
1,000 mg (n = 2)
900 mg (n = 10)
650 mg (n = 13)
500 mg (n = 13)
Fig 3. Median steady-state serum concentration profiles at each daily dose
of lapatinib.
Table 4. Lapatinib Steady-State Pharmacokinetic Parameters
AUC (h . g/mL) Cmax (g/mL) Cmin (g/mL)
Daily Dose (mg) Geometric Mean 95% CI Geometric Mean 95% CI Geometric Mean 95% CI
500 13.9 9.94 to 19.6 1.02 0.76 to 1.38 0.28 0.18 to 0.43
650 15.7 11.9 to 20.8 1.30 0.98 to 1.72 0.35 0.24 to 0.50
900 23.3 16.3 to 33.4 1.70 1.21 to 2.40 0.57 0.35 to 0.92
1,000 23.6 20.6 to 27.1 1.85 1.40 to 2.45 0.49 0.05 to 5.23
1,200 14.3 9.42 to 21.8 1.22 0.90 to 1.65 0.30 0.19 to 0.48
1,600 29.4 15.9 to 54.3 2.13 1.36 to 3.35 0.64 0.28 to 1.49





















500 650 900-1,000 1,200 1,600
Fig 4. Clinical response in relation to lapatinib dose. PR, partial response;
SD, stable disease 6 months; NR, nonresponders.
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Further evidence for the clinical activity of lapatinib in
heavily pretreated patients with advanced solid tumors was
presented in two studies.26,30 Minami et al30 reported that
two patients had PR: one with breast cancer treated with
lapatinib 1,600mg once daily, and the other with squamous
cell carcinoma of the lung treated with lapatinib 900 mg
oncedaily. Twelvepatients (NSCLC[nZ6], colorectal can-
cer [nZ 3], breast cancer [nZ 1], cervical cancer [nZ 1],
ovarian cancer [nZ1]) hadSDandeight of 14patientswith
clinical activity remainedon lapatinib therapy formore than
3 months. Versola et al26 reported a CR in a patient with an
ErbB1-overexpressing head and neck squamous cell car-
cinoma. Twenty-two patients with various tumors, most
expressing either ErbB1 or ErbB2, experienced SD with
a median duration of 4 months (range 1-13 months).26
Together, these studies indicate thepotential clinical activity
of lapatinib in patients with a variety of solid tumors.
The pharmacokinetics of lapatinib upon repeated dos-
ing display a time-dependent increase in systemic exposure
as described previously.25 For this reason, half-lives and
areas under the curve (AUCs) after a single or first dose
do not predict accumulation or steady-state concentration,
which represents the therapeutically relevant systemic expo-
sure for this chronic therapy. Thepharmacokinetics of lapa-
tinib in this study were, on average, similar, but exhibited
greater variability than in previous studies of either healthy
volunteers or cancer patients.25,31 This difference may be
secondary to allowing consumption of food with the doses
ondays 2 through 19or the effect of concurrentmedications
required by patients that could alter the absorption and/or
metabolism of lapatinib. Absorption of lapatinib is re-
stricted by low solubility and first-pass metabolism by
CYP3A4/5, which likely contribute to the variability in
systemic exposure. Transporters may also be involved,
although lapatinib does not appear to be a substrate for
P-glycoprotein (ABCB1).
Clinical responses were generally associated with
doses in the middle of the range examined in this study.
In terms of either the administered dose or the resulting
serum concentration, clinical response was more often as-
sociated with doses of 900 to 1,200 mg daily. However, due
to the limited response data, it was not possible to ade-
quately characterize the relationship between clinical re-
sponse and drug exposure. In addition, there was no
clear distinction between responders (PR and SD  6
months) and nonresponders related to drug exposure,
suggesting that the distinction between responders and
nonresponders may lie in the inherent biologic profile
of the tumor, specifically, which signaling pathways are
operative, and which pathways are directly involved in reg-
ulating tumor cell growth and survival. If tumor cell sur-
vival is dependent upon pathways that can be abrogated by
lapatinib, then those tumors might be more likely to re-
spond to therapy. If tumors have developed mechanisms
to evade apoptosis, and lapatinib exerts its anti-tumor ef-
fects through activation of apoptosis,23,24 then those tu-
mors might be resistant to lapatinib therapy.27 Current
efforts are focused on identifying a tumor profile that
will predict for response to lapatinib therapy.
There has been considerable discussion regarding
whether skin rash is requisite to achieve clinical response
with ErbB1 inhibitors. In this study, the incidence and se-
verity of skin rash was not associated with clinical response
(Fig 5) as reported for other small-molecule ErbB inhibitors
(eg, gefitinib, erlotinib). This distinction, alongwith other dif-
ferences in biochemical and biologic activity, may relate to
the unique 4-anilinoquinazoline structure of lapatinib in con-
trast to either gefitinib or erlotinib, which are quinazolines.32
Lapatanib was well tolerated at doses ranging from 500
to 1,600mg once daily with grade 1 and 2 diarrhea and rash
as the most common drug-related toxicities. The associa-
tion between diarrhea and dose but not concentration sug-
gests that this toxicity evolves from a local effect on the gut
epithelium. Similar andmore severe toxicities have been re-
ported in studies of other small-moleculeErbB1 tyrosine ki-






















Fig 5. Clinical response in relation to lapatinib steady-state concentration.
PR, partial response; SD, stable disease 6 months; NR, nonresponders;
Cmin, steady-state trough concentration.



















Fig 6. Clinical response in relation to lapatinib dose categorized by oc-
currence of rash. PR, partial response; SD, stable disease  6 months; NR,
nonresponders.
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both reversible inhibitors of ErbB1, the most frequently re-
ported AEs were nausea, vomiting, acneiform rash, and di-
arrhea in patients treated with gefitinib,33 and diarrhea,
rash, nausea, headache, emesis, and fatigue in patients
with treated with erlotinib.34 Dose-limiting toxicities of
PKI166, a ErbB1 and ErbB2 tyrosine kinase inhibitor,
included grade 3 transaminase elevations, skin rash, and
diarrhea.35-37 Clinical studies of CI-1033, an irreversible
pan-ErbB inhibitor, have shown that the most frequently
reported AEs were grade 1 to 2 nausea, emesis, diarrhea,
acneiform rash, stomatitis,38 and asthenia.39 In addition,
reversible dose-limiting hypersensitivity reactions,38 grade
3 thrombocytopenia,40 anddose-limiting grade 3 stomatitis
have also been reported with CI-1033.41
Treatment with trastuzumab has been reported to be
associated with an increased incidence of reversible cardio-
myopathy. However, it is not known whether this effect is
specific to trastuzumab, or a class effect associated with
ErbB2 inhibition.42,43 No evidence of drug-related cardiac
dysfunction was observed in this study.
Clinical activity was observed at lapatinib daily doses
ranging from 500 to 1,600 mg, and most frequently at 900
to 1,200 mg, in heavily pretreated patients with metastatic
carcinomas overexpressing ErbB2 and/or expressing ErbB1.
Because drug exposure does not appear to distinguish
between responders and nonresponders, identification of
a tumor profile, based on biologic features, that predicts
for response to lapatinib is currently being investigated.
- - -
Acknowledgment
We thank the patients who participated in this study
and their families. We thank Terry Paul for his assistance
in the preparation of the manuscript, and Lini Pandite
and Elaine Paul for their critical review of the manuscript.
We also thank the staff at the study centers, in particular,
Elizabeth Humes, Henry Bell, Roxanne Williams-Truax,
Shawna Savage, Noel Willcutt, Sharon Calvert, and Leslie
Kosco, for their diligence in identifying and caring for the
patients who participated in the study.
Authors’ Disclosures of Potential Conflicts of Interest
Although all authors completed the disclosure declaration, the following authors or their immediate family members
indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part
of the investigation. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict
of interest policy, please refer to theAuthorDisclosureDeclarationand theDisclosuresofPotentialConflicts of Interest section
in Information for Contributors.
REFERENCES
1. Yarden Y, Sliwkowski MX: Untangling the
ErbB signaling network. Nat Rev Mol Cell Biol
2:127-137, 2001
2. Klapper LN, Kirschbaum MH, Sela M,
et al: Biochemical and clinical implications of
ErbB/HER signaling network of growth fac-
tor receptors. Adv Cancer Res 77:25-79,
2000
3. Slamon DJ, Clark GM, Wong SG,
et al: Human breast cancer: Correlation of
relapse and survival with amplification of the
HER-2/neu oncogene. Science 235:177-182,
1987
Authors Employment Leadership Consultant Stock Honoraria Research Funds Testimony Other
Howard Burris GlaxoSmithKline (A) GlaxoSmithKline (A)









Claire Dees GlaxoSmithKline (B)
Kimberly Blackwell GlaxoSmithKline (A)
Matthew Ellis GlaxoSmithKline (A)
Beth Overmoyer GlaxoSmithKline (A)
Suzanne Jones GlaxoSmithKline (A)
Jennifer Harris GlaxoSmithKline GlaxoSmithKline (A)
Deborah Smith GlaxoSmithKline
Kevin Koch GlaxoSmithKline GlaxoSmithKline (A)
Andrew Stead GlaxoSmithKline GlaxoSmithKline (B)
Steve Mangum GlaxoSmithKline GlaxoSmithKline (A)
Neil Spector GlaxoSmithKline
Dollar amount codes: (A)  $10,000 (B) $10,000-99,999 (C) $ $100,000 (N/R) Not Required
Burris et al
5312 JOURNAL OF CLINICAL ONCOLOGY
Downloaded from jco.ascopubs.org on November 2, 2010. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
4. Slamon D, Godolphin W, Jones LA, et al:
Studies of the HER-2/neu proto-oncogene in
human breast and ovarian cancer. Science 244:
707-712, 1989
5. Bacus SS, Zelnich CR, Plowman G, et al:
Expression of the erbB-2 family of growth
factor receptors and their ligands in breast
cancer: Implication for tumor biology and clinical
behavior. Am J Clin Pathol 102:S13-S24,
1994
6. Sainsbury JR, Malcolm AJ, Appleton DR,
et al: Presence of epidermal growth factor
receptors as an indicator of poor prognosis in
patients with breast cancer. J Clin Pathol 38:
1225-1228, 1985
7. Olayioye MA, Graus-Porta D, Beerli RR,
et al: ErbB-1 and ErbB-2 acquire distinct signal-
ing properties dependent upon their dimerization
partner. Mol Cell Biol 18:5042-5051, 1998
8. Ullrich A, Schlessinger J: Signal transduc-
tion by receptors with tyrosine kinase activity.
Cell 61:203-212, 1990
9. Fukazawa T, Miyake S, Band V, et al:
Tyrosine phosphorylation of Cbl upon epidermal
growth factor (EGF) stimulation and its associa-
tion with EGF receptor and downstream signal-
ing proteins. J Biol Chem 271:14554-14559,
1996
10. Hackel PO, Zwick E, Prenzel N, et al:
Epidermal growth factor receptors: Critical me-
diators of multiple receptor pathways. Curr Opin
Cell Biol 11:184-189, 1999
11. Tzahar E, Waterman H, Chen X, et al: A
hierarchical network of interreceptor interactions
determines signal transduction by Neu differen-
tiation factor/neuregulin and epidermal growth
factor. Mol Cell Biol 16:5276-5287, 1996
12. Lange CA, Richer JK, Shen T, et al:
Convergence of progesterone and epidermal
growth factor signaling in breast cancer: Poten-
tiation of mitogen-activated protein kinase path-
ways. J Biol Chem 273:31308-31316, 1998
13. Moyer JD, Barbacci EG, Iwata KK, et al:
Induction of apoptosis and cell cycle arrest by
OSI-774, an inhibitor of epidermal growth factor
receptor tyrosine kinase. Cancer Res 57:4838-
4848, 1997
14. Moasser MM, Basso A, Averbuch SD,
et al: The tyrosine kinase inhibitor ZD1839
(‘‘Iressa’’) inhibits HER2-driven signaling and
suppresses the growth of HER2-overexpressing
tumor cells. Cancer Res 61:7184-7188, 2001
15. Hudziak RM, Lewis GD, Winget M, et al: A
p185HER2 monoclonal antibody has antiprolifer-
ative effects in vitro and sensitizes human breast
tumor cells to tumor necrosis factor. Mol Cell
Biol 9:1165-1172, 1989
16. Moulder SL, Yakes FM, Muthuswamy SK,
et al: Epidermal growth factor receptor (HER1)
tyrosine kinase inhibitor ZD1839 (Iressa) inhibits
HER2/neu (erbB2)-overexpressing breast cancer
cells in vitro and in vivo. Cancer Res 61:8887-
8895, 2001
17. Ciardiello F, Caputo R, Bianco R, et al:
Antitumor effect and potentiation of cytotoxic
drugs activity in human cancer cells by ZD-1839
(Iressa), an epidermal growth factor receptor-
selective tyrosine kinase inhibitor. Clin Cancer
Res 6:2053-2063, 2000
18. Cobleigh MA, Vogel CL, Tripathy D, et al:
Multinational study of the efficacy and safety of
humanized anti-Her2 monoclonal antibody in
women who have Her2-overexpressing meta-
static breast cancer that has progressed after
chemotherapy for metastatic disease. J Clin
Oncol 17:2639-2648, 1999
19. Mendelsohn J, Baselga J: The EGF re-
ceptor as targets for cancer therapy. Oncogene
19:6550-6565, 2000
20. Hecht JR, Patnaik A, Malik I, et al: ABX-
EGF monotherapy in patients (pts) with meta-
static colorectal cancer (mCRC): An updated
analysis. Proc Am Soc Clin Oncol 23:248, 2004
(abstr 3511)
21. Vanhoefer U, Tewes M, Rojo F, et al:
Phase I study of the humanized antiepidermal
growth factor receptor monoclonal antibody
EMD72000 in patients with advanced solid
tumors that express the epidermal growth factor
receptor. J Clin Oncol 22:175-184, 2004
22. Trigo J, Hitt R, Koralewski P, et al: Cetux-
imab monotherapy is active in patients (pts) with
platinum-refractory recurrent/metastatic squa-
mous cell carcinoma of the head and neck
(SCCHN): Results of a phase II study, Proc Am
Soc Clin Oncol 23:487, 2004 (abstr 5502)
23. Xia W, Mullin RJ, Keith BR, et al: Anti-
tumor activity of GW572016: A dual tyrosine
kinase inhibitor blocks EGF activation of EGFR/
erbB2 and downstream Erk1/2 and AKT path-
ways. Oncogene 21:6255-6263, 2002
24. Rusnak DW, Lackey K, Affleck K, et al: The
effects of the novel, reversible epidermal growth
factor receptor/ErbB-2 tyrosine kinase inhibitor,
GW572016, on the growth of human normal and
tumor-derived cell lines in vitro and in vivo. Mol
Cancer Ther 1:85-94, 2001
25. Bence AK, Anderson EB, Doukas MA,
et al: Phase I pharmacokinetic studies evaluating
single and multiple doses of oral GW572016,
a dual EGFR-ErbB2 inhibitor, in healthy subjects.
Invest New Drugs 23:39-49, 2005
26. Versola M, Burris HA, Jones S, et al:
Clinical activity of GW572016 in EGF10003 in
patients with solid tumors. Proc Am Soc Clin
Oncol 23: 2004 (abstr 3047)
27. Spector NL, Xia W, Burris H, III, et al:
Study of the biological effects of lapatinib,
a reversible inhibitor of ErbB1 and ErbB2
tyrosine kinases, on tumor growth and survival
pathways in patients with advanced malignan-
cies. J Clin Oncol 23:1-11, 2005
28. Hsieh S, Tobien T, Koch K, et al: Increasing
throughput of parallel on-line extraction liquid
chromatography/electrospray ionization tandem
mass spectrometry system for GLP quantitative
bioanalysis in drug development. Rapid Com-
mun Mass Spectrom 18:285-292, 2004
29. Therasse P, Arbuck SG, Eisenhauer EA,
et al: New guidelines to evaluate the response to
treatment in solid tumors. J Natl Cancer Inst
92:205-216, 2000
30. Minami H, Nakagawa K, Kawada K, et al: A
phase I study of GW572016 in patients with
solid tumors. Proc Am Soc Clin Oncol 22:14S,
2004 (abstr 3048)
31. Koch KM, Lee D, Jones S, et al: Pharma-
cokinetics of GW572016 in an ascending dose
tolerability study of phase I cancer patients. Eur
J Cancer 1:S169, 2003 (poster 559)
32. Wood ER, Truesdale AT, McDonald OB,
et al: A unique structure for epidermal growth
factor receptor bound to GW572016 (Lapatinib):
Relationships among protein conformation, in-
hibitor off-rate, and receptor activity in tumor
cells. Cancer Res 64:6652-6659, 2004
33. Baselga J, Rischin D, Ranson M, et al:
Phase I safety, pharmacokinetic, and pharmaco-
dynamic trial of ZD1839, a selective oral epider-
mal growth factor receptor tyrosine kinase
inhibitor, in patients with five selected tumor
types. J Clin Oncol 20:4292-4302, 2002
34. Hidalgo M, Siu LL, Nemunaitis J, et al:
Phase I and pharmacologic study of OSI- 774,
an epidermal growth factor receptor tyrosine
kinase inhibitor, in patients with advanced solid
malignancies. J Clin Oncol 19:3267-3279,
2001
35. Hoekstra R, Dumez H, van Oosterom AT,
et al: A phase I and pharmacological study of
PKI166, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, administered
orally in a two weeks on, two weeks off scheme
to patients with advanced cancer. Proc Am Soc
Clin Oncol 21, 2002 (abstr 340)
36. Dumez H, Hoekstra R, Eskens F, et al:
A phase I and pharmacological study of PKI166,
an epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, administered orally 3
times a week to patients with advanced can-
cer. Proc Am Soc Clin Oncol 21, 2002 (abstr
341)
37. Murren JR, Papadimitrakopoulou VA, Sizer
KC, et al: A phase I dose-escalating study to
evaluate the biological activity and pharmacoki-
netics of PKI166, a novel tyrosine kinase in-
hibitor, in patients with advanced cancers. Proc
Am Soc Clin Oncol 21, 2002 (abstr 377)
38. Garrison MA, Tolcher A, McCreery H, et al:
A phase I and pharmacokinetic study of oral
CI-1033, a pan-erbB tyrosine kinase inhibitor,
given orally on days 1, 8, and 15 every 28 days to
patients with solid tumors. Proc Am Soc Clin
Oncol 20:72a, 2001 (abstr 283)
39. Nemunaitis JJ, Eiseman C, Cunningham C,
et al: A phase I trial of CI-1033, a pan-erbB
tyrosine kinase inhibitor, given daily for 14 days
every 3 weeks, in patients with solid advanced
tumors. Proc Am Soc Clin Oncol 22:243, 2003
(abstr 974)
40. Rinehart JJ, Wilding G, Willson J, et al: A
phase I clinical and pharmacokinetic study of oral
CI-1033, a pan-erbB tyrosine kinase inhibitor, in
patients with advanced solid tumors. Proc Am
Soc Clin Oncol 21:11a, 2002 (abstr 41)
41. Shin DM, Nemunaitis JJ, Zinner RG, et al:
A phase I biomarker study of CI-1033, a novel
pan-erbB tyrosine kinase inhibitor in patients
with solid tumors. Proc Am Soc Clin Oncol
20:82a, 2001 (abstr 324)
42. Seidman A, Hudis C, Pierri MK, et al: Car-
diac dysfunction in the trastuzumab clinical
trials experience. J Clin Oncol 20:1215-1221,
2002
43. Suter TM, Cook-Burns N, Barton C: Car-
diotoxicity associated with trastuzumab (Hercep-
tin) therapy in the treatment of metastatic breast
cancer. Breast 13:173-183, 2004
Study of Lapatinib in Metastatic Carcinomas
www.jco.org 5313
Downloaded from jco.ascopubs.org on November 2, 2010. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
